Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma
G Li, D Wang, Y Zhai, C Pan, J Zhang, C Wang… - Cell Metabolism, 2024 - cell.com
Patients with high ALDH1A3-expressing glioblastoma (ALDH1A3 hi GBM) show limited
benefit from postoperative chemoradiotherapy. Understanding the mechanisms underlying …
benefit from postoperative chemoradiotherapy. Understanding the mechanisms underlying …
[HTML][HTML] Applications of genome-scale metabolic models to the study of human diseases: A systematic review
Abstract Background and Objectives: Genome-scale metabolic networks (GEMs) represent a
valuable modeling and computational tool in the broad field of systems biology. Their ability …
valuable modeling and computational tool in the broad field of systems biology. Their ability …
[HTML][HTML] Why Do Glioblastoma Treatments Fail?
A Rončević, N Koruga, A Soldo Koruga… - Future …, 2025 - mdpi.com
Glioblastoma (GBM) is the most aggressive brain tumor, characterized by high recurrence
rates and poor patient outcomes. Treatment failure is driven by multiple factors, including …
rates and poor patient outcomes. Treatment failure is driven by multiple factors, including …